Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,582 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Kotsia A, Brilakis ES, Held C, Cannon C, Steg GP, Meier B, Cools F, Claeys MJ, Cornel JH, Aylward P, Lewis BS, Weaver D, Brandrup-Wognsen G, Stevens SR, Himmelmann A, Wallentin L, James SK. Kotsia A, et al. Among authors: cannon c. Am Heart J. 2014 Jul;168(1):68-75.e2. doi: 10.1016/j.ahj.2014.04.001. Epub 2014 Apr 13. Am Heart J. 2014. PMID: 24952862 Clinical Trial.
Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E. Cannon CP, et al. Circulation. 1998 Feb 3;97(4):340-9. doi: 10.1161/01.cir.97.4.340. Circulation. 1998. PMID: 9468207 Clinical Trial.
Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia.
Borzak S, Cannon CP, Kraft PL, Douthat L, Becker RC, Palmeri ST, Henry T, Hochman JS, Fuchs J, Antman EM, McCabe C, Braunwald E. Borzak S, et al. Among authors: cannon cp. Am J Cardiol. 1998 Mar 15;81(6):678-81. doi: 10.1016/s0002-9149(97)01006-0. Am J Cardiol. 1998. PMID: 9527073 Clinical Trial.
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.
Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, Bluhmki E, Sarelin H, Wang-Clow F, Fox NL, Braunwald E. Van de Werf F, et al. Among authors: cannon cp. Am Heart J. 1999 May;137(5):786-91. doi: 10.1016/s0002-8703(99)70400-x. Am Heart J. 1999. PMID: 10220625 Clinical Trial.
Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program.
Cannon CP, Hand MH, Bahr R, Boden WE, Christenson R, Gibler WB, Eagle K, Lambrew CT, Lee TH, MacLeod B, Ornato JP, Selker HP, Steele P, Zalenski RJ; National Heart Attack Alert Program (NHAAP) Coordinating Committee Critical Pathways Writing Group. Cannon CP, et al. Am Heart J. 2002 May;143(5):777-89. doi: 10.1067/mhj.2002.120260. Am Heart J. 2002. PMID: 12040337 Review.
1,582 results